Antibody‐drug conjugates (ADCs), chemotherapeutic agents conjugated to an antibody to enhance their targeted delivery to tumors, represent a significant advancement in cancer therapy. ADCs combine the precise targeting capabilities of antibodies and the potent cell‐killing effects of chemotherapy, allowing for enhanced cytotoxicity to tumors while minimizing damage to healthy tissues. Here, we provide an overview of the current clinical landscape of ADCs, highlighting 11 U.S. Food and Drug Administration (FDA)‐approved products and discussing over 500 active clinical trials investigating newer ADCs. We also discuss some key challenges associated with the clinical translation of ADCs and highlight emerging strategies to overcome these hurdles. Our discussions will provide useful guidelines for the future development of safer and more effective ADCs for a broader range of indications.

中文翻译：

---

临床上的抗体药物偶联物


抗体-药物偶联物 （ADC） 是与抗体偶联以增强其对肿瘤的靶向递送的化疗药物，代表了癌症治疗的重大进步。ADC 结合了抗体的精确靶向能力和化疗的强效细胞杀伤作用，可以增强对肿瘤的细胞毒性，同时最大限度地减少对健康组织的损害。在这里，我们概述了 ADC 的当前临床形势，重点介绍了 11 种美国食品和药物管理局 （FDA） 批准的产品，并讨论了 500 多项研究新型 ADC 的活跃临床试验。我们还讨论了与 ADC 临床转化相关的一些关键挑战，并重点介绍了克服这些障碍的新兴策略。我们的讨论将为未来针对更广泛的适应症开发更安全、更有效的 ADC 提供有用的指导。